谷氨酰胺代谢相关蛋白在肿瘤转移中的作用研究进展

doi:10.19401/j.cnki.1007-3639.2024.01.007

中国癌症杂志 ›› 2024, Vol. 34 ›› Issue (1): 97-103.doi: 10.19401/j.cnki.1007-3639.2024.01.007

谷氨酰胺代谢相关蛋白在肿瘤转移中的作用研究进展

刘雪柔¹^,²(), 杨玉梅¹^,², 赵倩¹^,², 荣翔宇¹^,², 刘伟¹^,², 郑瑞洁¹^,², 庞金龙¹^,², 李娴¹^,², 李姗姗¹^,²()

1.蚌埠医科大学药学院，安徽蚌埠 233030
2.安徽省生化药物工程技术研究中心，安徽蚌埠 233030

收稿日期:2023-10-26 修回日期:2023-12-20 出版日期:2024-01-30 发布日期:2024-02-05
通信作者: 李姗姗（ORCID: 0000-0003-2201-6321），博士，副教授、硕士研究生导师。
作者简介:刘雪柔（ORCID: 0009-0004-2260-8153），硕士。
基金资助:
安徽省重点研究与开发计划项目(202104g01020017);安徽省重点生化工程中心科研平台开放课题(2023SYKFD05);安徽省自然科学基金(1908085QH373);国家级大学生创新创业训练计划项目(202210367064);安徽高校自然科学研究项目(KJ2021A0702)

Research progress on the role of glutamine metabolism-related proteins in tumor metastasis

LIU Xuerou¹^,²(), YANG Yumei¹^,², ZHAO Qian¹^,², RONG Xiangyu¹^,², LIU Wei¹^,², ZHENG Ruijie¹^,², PANG Jinlong¹^,², LI Xian¹^,², LI Shanshan¹^,²()

1. School of Pharmacy, Bengbu Medical University, Bengbu 233030, Anhui Province, China
2. Anhui Provincial Engineering Technology Research Center of Biochemical Pharmaceuticals, Bengbu 233030, Anhui Province, China

Received:2023-10-26 Revised:2023-12-20 Published:2024-01-30 Online:2024-02-05
Contact: LI Shanshan.

摘要/Abstract

摘要：

肿瘤转移是导致癌症患者高死亡率的主要原因。谷氨酰胺在肿瘤的恶性进展中发挥重要作用，近年来研究发现，谷氨酰胺与肿瘤转移密切相关，谷氨酰胺作为肿瘤细胞重要的碳源和氮源，不仅影响肿瘤细胞的增殖，还参与调控肿瘤细胞的迁移和侵袭。此外，谷氨酰胺代谢过程中的各种酶及转运体通过不同的信号转导通路参与肿瘤转移过程。本文综述近年来谷氨酰胺在肿瘤转移中作用的研究进展，并梳理有关治疗靶点，以期为临床治疗肿瘤转移提供新的策略。

关键词: 谷氨酰胺代谢, 肿瘤转移, 上皮-间质转化, 靶向治疗

Abstract:

Tumor metastasis is closely related to high mortality rate of cancer. It is well known that glutamine plays an important role in the malignant progression of cancer. Notably, as an important carbon and nitrogen donor, glutamine has been found to be closely related to tumor metastasis in recent years. Glutamine is not only involved in regulating the proliferation of tumor cells, but is also closely related to the migration and invasion of tumor cells. Furthermore, various enzymes along with transporters in the metabolism of glutamine are involved in the process of tumor metastasis through different signaling pathways. This review provided a summary of the role of glutamine in tumor metastasis in recent years and proposed therapeutic targets to provide new strategies for the clinical treatment of tumor metastases.

Key words: Glutamine metabolism, Tumor metastasis, Epithelial-mesenchymal transition, Targeted therapy

中图分类号:

R73-37

刘雪柔, 杨玉梅, 赵倩, 荣翔宇, 刘伟, 郑瑞洁, 庞金龙, 李娴, 李姗姗. 谷氨酰胺代谢相关蛋白在肿瘤转移中的作用研究进展[J]. 中国癌症杂志, 2024, 34(1): 97-103.

LIU Xuerou, YANG Yumei, ZHAO Qian, RONG Xiangyu, LIU Wei, ZHENG Ruijie, PANG Jinlong, LI Xian, LI Shanshan. Research progress on the role of glutamine metabolism-related proteins in tumor metastasis[J]. China Oncology, 2024, 34(1): 97-103.

图/表 2

参考文献 66

[1]	REN L, RUIZ-RODADO V, DOWDY T, et al. Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma[J]. Cancer Metab, 2020, 8: 4. doi: 10.1186/s40170-020-0209-8 pmid: 32158544
[2]	FARES J, FARES M Y, KHACHFE H H, et al. Molecular principles of metastasis: a hallmark of cancer revisited[J]. Signal Transduct Target Ther, 2020, 5(1): 28.
[3]	BERGERS G, FENDT S M. The metabolism of cancer cells during metastasis[J]. Nat Rev Cancer, 2021, 21(3): 162-180. doi: 10.1038/s41568-020-00320-2 pmid: 33462499
[4]	LEONE R D, ZHAO L, ENGLERT J M, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion[J]. Science, 2019, 366(6468): 1013-1021. doi: 10.1126/science.aav2588 pmid: 31699883
[5]	WANG Y Y, BAI C S, RUAN Y X, et al. Coordinative metabolism of glutamine carbon and nitrogen in proliferating cancer cells under hypoxia[J]. Nat Commun, 2019, 10(1): 201. doi: 10.1038/s41467-018-08033-9 pmid: 30643150
[6]	KODAMA M, OSHIKAWA K, SHIMIZU H, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer[J]. Nat Commun, 2020, 11(1): 1320. doi: 10.1038/s41467-020-15136-9 pmid: 32184390
[7]	ADHIKARY G, SHRESTHA S, NASELSKY W, et al. Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation[J]. Mol Carcinog, 2023, 62(4): 438-449. doi: 10.1002/mc.v62.4
[8]	JIANG B, ZHANG J, ZHAO G H, et al. Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis[J]. Mol Cell, 2022, 82(10): 1821-1835.e6. doi: 10.1016/j.molcel.2022.03.016 pmid: 35381197
[9]	VILLAR V H, ALLEGA M F, DESHMUKH R, et al. Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer[J]. Nat Chem Biol, 2023, 19(3): 292-300. doi: 10.1038/s41589-022-01154-9
[10]	SHANG M, CAPPELLESSO F, AMORIM R, et al. Macrophage-derived glutamine boosts satellite cells and muscle regeneration[J]. Nature, 2020, 587(7835): 626-631. doi: 10.1038/s41586-020-2857-9
[11]	DORAI T, PINTO J T, DENTON T T, et al. The metabolic importance of the glutaminase Ⅱ pathway in normal and cancerous cells[J]. Anal Biochem, 2022, 644: 114083. doi: 10.1016/j.ab.2020.114083
[12]	YOO H C, PARK S J, NAM M, et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells[J]. Cell Metab, 2020, 31(2): 267-283.e12. doi: S1550-4131(19)30664-3 pmid: 31866442
[13]	GUO C S, YOU Z Y, SHI H, et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity[J]. Nature, 2023, 620(7972): 200-208. doi: 10.1038/s41586-023-06299-8
[14]	LIU R, HONG R X, WANG Y, et al. Defect of SLC38A3 promotes epithelial-mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma[J]. Chung Kuo Yen Cheng Yen Chiu, 2020, 32(5): 547-563.
[15]	CHEN Y Y, TAN L, GAO J, et al. Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics[J]. Eur J Med Chem, 2023, 252: 115306. doi: 10.1016/j.ejmech.2023.115306
[16]	HAN T Y, WANG P C, WANG Y N, et al. FAIM regulates autophagy through glutaminolysis in lung adenocarcinoma[J]. Autophagy, 2022, 18(6): 1416-1432. doi: 10.1080/15548627.2021.1987672
[17]	YU Y, YU X H, FAN C L, et al. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer[J]. J Mol Med, 2018, 96(8): 777-790. doi: 10.1007/s00109-018-1659-0
[18]	LIU H Y, ZHANG H S, LIU M Y, et al. GLS1 depletion inhibited colorectal cancer proliferation and migration via redox/Nrf2/autophagy-dependent pathway[J]. Arch Biochem Biophys, 2021, 708: 108964. doi: 10.1016/j.abb.2021.108964
[19]	CAI J, CHEN Z Q, WANG J G, et al. circHECTD1 facilitates glutaminolysis to promote gastric cancer progression by targeting miR-1256 and activating β-catenin/c-Myc signaling[J]. Cell Death Dis, 2019, 10(8): 576. doi: 10.1038/s41419-019-1814-8 pmid: 31371702
[20]	PASTUSHENKO I, BLANPAIN C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. doi: S0962-8924(18)30201-0 pmid: 30594349
[21]	LI B H, CAO Y J, MENG G, et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway[J]. EBioMedicine, 2019, 39: 239-254. doi: S2352-3964(18)30567-X pmid: 30555042
[22]	LUKEY M J, CLUNTUN A A, KATT W P, et al. Liver-type glutaminase GLS2 is a druggable metabolic node in luminal-subtype breast cancer[J]. Cell Rep, 2019, 29(1): 76-88.e7. doi: S2211-1247(19)31131-3 pmid: 31577957
[23]	SUZUKI S, VENKATESH D, KANDA H, et al. GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma[J]. Cancer Res, 2022, 82(18): 3209-3222.
[24]	ZHANG C, LIU J, ZHAO Y H, et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis[J]. Elife, 2016, 5: e10727. doi: 10.7554/eLife.10727
[25]	KUO T C, CHEN C K, HUA K T, et al. Glutaminase 2 stabilizes dicer to repress snail and metastasis in hepatocellular carcinoma cells[J]. Cancer Lett, 2016, 383(2): 282-294. doi: 10.1016/j.canlet.2016.10.012
[26]	DIAS M M, ADAMOSKI D, DOS REIS L M, et al. GLS2 is protumorigenic in breast cancers[J]. Oncogene, 2020, 39(3): 690-702. doi: 10.1038/s41388-019-1007-z pmid: 31541193
[27]	BRABLETZ S, SCHUHWERK H, BRABLETZ T, et al. Dynamic EMT: a multi-tool for tumor progression[J]. EMBO J, 2021, 40(18): e108647. doi: 10.15252/embj.2021108647
[28]	NALLASAMY P, NIMMAKAYALA R K, KARMAKAR S, et al. Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1-CD44 axis[J]. Gastroenterology, 2021, 161(6): 1998-2013.e7. doi: 10.1053/j.gastro.2021.08.023 pmid: 34418441
[29]	XIE W, JIANG Q W, WU X J, et al. IKBKE phosphorylates and stabilizes Snail to promote breast cancer invasion and metastasis[J]. Cell Death Differ, 2022, 29(8): 1528-1540. doi: 10.1038/s41418-022-00940-1 pmid: 35066576
[30]	LEE M Y, LIM S, KIM Y S, et al. DEP-induced ZEB2 promotes nasal polyp formation via epithelial-to-mesenchymal transition[J]. J Allergy Clin Immunol, 2022, 149(1): 340-357. doi: 10.1016/j.jaci.2021.04.024
[31]	LIANG Y P, CEN J J, HUANG Y, et al. CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug[J]. Mol Cancer, 2022, 21(1): 224. doi: 10.1186/s12943-022-01694-7 pmid: 36536414
[32]	ANG H L, MOHAN C D, SHANMUGAM M K, et al. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds[J]. Med Res Rev, 2023, 43(4): 1141-1200. doi: 10.1002/med.v43.4
[33]	RECOUVREUX M V, MOLDENHAUER M R, GALENKAMP K M O, et al. Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer[J]. J Exp Med, 2020, 217(9): e20200388. doi: 10.1084/jem.20200388
[34]	CHEN X T, HUANG L L, YANG T T, et al. METTL3 promotes esophageal squamous cell carcinoma metastasis through enhancing GLS2 expression[J]. Front Oncol, 2021, 11: 667451. doi: 10.3389/fonc.2021.667451
[35]	KIM G W, LEE D H, JEON Y H, et al. Glutamine synthetase as a therapeutic target for cancer treatment[J]. Int J Mol Sci, 2021, 22(4): 1701. doi: 10.3390/ijms22041701
[36]	ZHANG R, ZHU J C, HU H, et al. MicroRNA-140-5p suppresses invasion and proliferation of glioma cells by targeting glutamate-ammonia ligase (GLUL)[J]. Neoplasma, 2020, 67(2): 371-378. doi: 10.4149/neo_2020_190514N432 pmid: 31986891
[37]	MENGA A, FAVIA M, SPERA I, et al. N-acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages[J]. EMBO Rep, 2021, 22(9): e51981. doi: 10.15252/embr.202051981
[38]	XUAN D T M, WU C C, WANG W J, et al. Glutamine synthetase regulates the immune microenvironment and cancer development through the inflammatory pathway[J]. Int J Med Sci, 2023, 20(1): 35-49. doi: 10.7150/ijms.75625 pmid: 36619229
[39]	QUAIL D F, JOYCE J A. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-1437. doi: 10.1038/nm.3394 pmid: 24202395
[40]	LIN Y X, XU J X, LAN H Y. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications[J]. J Hematol Oncol, 2019, 12(1): 76. doi: 10.1186/s13045-019-0760-3
[41]	WANG Y, GAO R F, LI J P, et al. Downregulation of hsa_circ_0074854 suppresses the migration and invasion in hepatocellular carcinoma via interacting with HuR and via suppressing exosomes-mediated macrophage M2 polarization[J]. Int J Nanomedicine, 2021, 16: 2803-2818. doi: 10.2147/IJN.S284560
[42]	WEI C, YANG C G, WANG S Y, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis[J]. Mol Cancer, 2019, 18(1): 64. doi: 10.1186/s12943-019-0976-4 pmid: 30927925
[43]	PALMIERI E M, MENGA A, MARTÍN-PÉREZ R, et al. Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis[J]. Cell Rep, 2017, 20(7): 1654-1666. doi: S2211-1247(17)31033-1 pmid: 28813676
[44]	MENGA A, SERRA M, TODISCO S, et al. Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages[J]. EMBO Mol Med, 2020, 12(10): e11210. doi: 10.15252/emmm.201911210
[45]	WANG T, CAI B L, DING M C, et al. C-myc overexpression promotes oral cancer cell proliferation and migration by enhancing glutaminase and glutamine synthetase activity[J]. Am J Med Sci, 2019, 358(3): 235-242. doi: S0002-9629(19)30219-8 pmid: 31324362
[46]	BODINEAU C, TOMÉ M, MURDOCH P D S, et al. Glutamine, MTOR and autophagy: a multiconnection relationship[J]. Autophagy, 2022, 18(11): 2749-2750. doi: 10.1080/15548627.2022.2062875
[47]	JIN L T, CHUN J, PAN C Y, et al. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer[J]. Mol Cell, 2018, 69(1): 87-99.e7. doi: S1097-2765(17)30884-5 pmid: 29249655
[48]	KANG J, CHUN J, HWANG J S, et al. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer[J]. Cell Rep, 2022, 41(11): 111827. doi: 10.1016/j.celrep.2022.111827
[49]	LIU G J, ZHU J, YU M L, et al. Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients[J]. J Transl Med, 2015, 13: 144. doi: 10.1186/s12967-015-0500-6 pmid: 25947346
[50]	MAO L, HONG X, XU L W, et al. Sirtuin 4 inhibits prostate cancer progression and metastasis by modulating p21 nuclear translocation and glutamate dehydrogenase 1 ADP-ribosylation[J]. J Oncol, 2022, 2022: 5498743.
[51]	LEE H T, HUANG C H, CHEN W C, et al. Transglutaminase 2 promotes migration and invasion of lung cancer cells[J]. Oncol Res, 2018, 26(8): 1175-1182. doi: 10.3727/096504018X15149761920868
[52]	ECKERT R L. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target[J]. Mol Carcinog, 2019, 58(6): 837-853. doi: 10.1002/mc.v58.6
[53]	KANG S, OH S C, MIN B W, et al. Transglutaminase 2 regulates self-renewal and stem cell marker of human colorectal cancer stem cells[J]. Anticancer Res, 2018, 38(2): 787-794. pmid: 29374703
[54]	JIA C C, WANG G Y, WANG T T, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition via the transglutaminase 2-dependent IL-6/IL6R/STAT3 axis in hepatocellular carcinoma[J]. Int J Biol Sci, 2020, 16(14): 2542-2558. doi: 10.7150/ijbs.45446
[55]	ASHOUR A A, GURBUZ N, ALPAY S N, et al. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion[J]. J Cell Mol Med, 2014, 18(11): 2235-2251. doi: 10.1111/jcmm.12361 pmid: 25215932
[56]	WANG X F, YU Z J, ZHOU Q, et al. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway[J]. Oncotarget, 2016, 7(6): 7066-7079. doi: 10.18632/oncotarget.6883 pmid: 26771235
[57]	DING Y, LIU P F, ZHANG S S, et al. Screening pathogenic genes in oral squamous cell carcinoma based on the mRNA expression microarray data[J]. Int J Mol Med, 2018, 41(6): 3597-3603. doi: 10.3892/ijmm.2018.3514 pmid: 29512771
[58]	CSANADI A, OSER A, AUMANN K, et al. Overexpression of SLC1a5 in lymph node metastases outperforms assessment in the primary as a negative prognosticator in non-small cell lung cancer[J]. Pathology, 2018, 50(3): 269-275. doi: 10.1016/j.pathol.2017.10.016
[59]	DING M C, BU X, LI Z H, et al. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2[J]. Int J Biol Sci, 2020, 16(16): 3100-3115. doi: 10.7150/ijbs.48066
[60]	WANG Y H, FU L, CUI M Q, et al. Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1[J]. Cancer Lett, 2017, 393: 8-15. doi: S0304-3835(17)30078-2 pmid: 28202352
[61]	ZHANG D J, ZHAO L, SHEN Q, et al. Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer[J]. Int J Cancer, 2017, 140(10): 2298-2309. doi: 10.1002/ijc.30656 pmid: 28213952
[62]	MOROTTI M, ZOIS C E, EL-ANSARI R, et al. Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer[J]. Br J Cancer, 2021, 124(2): 494-505. doi: 10.1038/s41416-020-01113-y
[63]	NAJUMUDEEN A K, CETECI F, FEY S K, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer[J]. Nat Genet, 2021, 53(1): 16-26. doi: 10.1038/s41588-020-00753-3 pmid: 33414552
[64]	INNAO V, RIZZO V, ALLEGRA A G, et al. Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma[J]. Cells, 2021, 10(2): 439. doi: 10.3390/cells10020439
[65]	RICHARD S M, MARTINEZ MARIGNAC V L. Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition[J]. J Cancer Res Ther, 2015, 11(2): 336-340. doi: 10.4103/0973-1482.157317 pmid: 26148596
[66]	HALAMA A, KULINSKI M, DIB S S, et al. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis[J]. Cancer Lett, 2018, 430: 133-147. doi: S0304-3835(18)30342-2 pmid: 29777783

谷氨酰胺代谢相关蛋白在肿瘤转移中的作用研究进展

Research progress on the role of glutamine metabolism-related proteins in tumor metastasis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 66

相关文章 15

编辑推荐

Metrics

本文评价

[1]	康殷楠, 陈顺, 解有成, 郑英, 何昱静, 李初谊, 于晓辉. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 790-800.
[2]	吴晶, 周娟, 苏春霞. 肺癌脂肪酸代谢重编程的研究进展[J]. 中国癌症杂志, 2023, 33(5): 517-526.
[3]	蒋金玲, 周尘飞, 王超, 赵丽琴, 吴珺玮, 张俊. 2022年度胃癌研究和诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 303-314.
[4]	田熙, 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟. 2022年度肾细胞癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 191-200.
[5]	苏春霞, 周彩存. 2022年度肺癌领域重要临床研究进展[J]. 中国癌症杂志, 2023, 33(3): 218-227.
[6]	曹晓珊, 丛斌斌. 三阳性乳腺癌内分泌治疗联合靶向治疗的研究进展[J]. 中国癌症杂志, 2023, 33(3): 288-292.
[7]	邵志博, 杨犇龙, 吴炅. 2022年中国乳腺癌重要临床试验成果及最新进展[J]. 中国癌症杂志, 2023, 33(2): 103-109.
[8]	郭晴, 张剑. HER2低表达乳腺癌的靶向治疗研究进展[J]. 中国癌症杂志, 2023, 33(2): 181-190.
[9]	夏玲芳, 朱俊, 吴小华. 2023年ESMO妇科肿瘤治疗最新进展及展望[J]. 中国癌症杂志, 2023, 33(11): 969-980.
[10]	高鹤丽, 徐近, 陈洁, 虞先濬. 胰腺神经内分泌瘤的精准诊疗进展[J]. 中国癌症杂志, 2023, 33(11): 993-1001.
[11]	赵博伦, 朱冠男. NRAS突变型晚期黑色素瘤的治疗进展[J]. 中国癌症杂志, 2023, 33(10): 936-944.
[12]	肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[13]	李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测：现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518.
[14]	张起翔, 尤永平. ZDHHC12在胶质母细胞瘤中通过YAP1调控肿瘤特性[J]. 中国癌症杂志, 2022, 32(6): 527-534.
[15]	曲以平, 侯鹏. 转移性儿童甲状腺癌的遗传学特征和预后[J]. 中国癌症杂志, 2022, 32(5): 373-379.